Abeome is a privately held pre-clinical stage biotechnology company focused on deploying its proprietary transgenic mouse, AbeoMouse, in the discovery of novel monoclonal antibodies in therapeutic areas with large unmet medical needs with significant revenue potential (immune diseases, oncology, and obesity). Abeome's technology platforms offer the ability to rapidly discover antibodies for both licensure as well as in-house development.